A Phase 1, Open-Label Study in Healthy Participants Aged 18 to 65 Years to Investigate the CYP3A4 Induction Potential of GSK3882347
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Period 1: Cmax of 1-hydroxy-MDZ
研究概览
简要总结
The objective of this study is to determine the magnitude and clinical relevance of a potential drug-drug interaction of GSK3882347 with midazolam (MDZ) in healthy participants. This study assesses the effect of GSK3882347 as an inducer of Cytochrome P450 3A4 (CYP3A4) using MDZ, a sensitive substrate of hepatic and intestinal CYP3A4. The study will investigate MDZ pharmacokinetic (PK) effect in two dosing periods:
Period 1: A single dose of MDZ Period 2: 14-days of once daily repeat dosing of GSK3882347 followed by single dose of MDZ co-administered with GSK3882347 on Day 15 (14-days has been selected as this duration is required in order to maximize any potential CYP3A4 enzyme induction).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
This is an open-label study.
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •History or presence of significant cardiovascular, respiratory, hepatic, renal, urological, gastrointestinal, metabolic, endocrinological, hematological, immunologic, dermatologic, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data or in the opinion of the investigator places the participants at unacceptable risk or would make adhering to study procedures for the duration of the study difficult. Participants who have had a gastric bypass or a cholecystectomy are excluded from the study.
- •Abnormal blood pressure, as determined by the investigator.
- •Alanine transferase (ALT) value greater than (>)1.5 × upper limit of normal (ULN).
- •Bilirubin value >1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •The participant has a current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •The participant has congenital long QT syndrome or known prolongation of the corrected QT (QTc) interval.
- •The participant has any history of heart failure.
- •The participant has a family history of QT prolongation or sudden death.
- •The participant has any current or previous a history of episodes of symptomatic bradycardia or bradyarrhythmia.
- •The participant has a QTc >450 millisecond (msec). Note: The QTc is the QT interval corrected for heart rate according to Fridericia formula, machine, or manual overread.
- •The participant has anuria, oliguria, or impairment of renal function (GFR by Modification of diet in renal disease [MDRD] <90 milliliter per minute per 1.73 meter square [mL/min/1.73m^2] or serum creatinine > ULN or urine albumin-creatinine ratio [ACR] of ≥300 milligram per gram [mg/g] at screening).
- •The participant must agree to and adhere to the concomitant therapy (including nondrug therapies) restrictions from the Screening Visit through to the end of the end of the study (including telephone visit).
- •Participation in the study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 56 days.
- •Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
- •Current enrolment or past participation within the last 30 days or 5 half-lives, whichever is longer, before signing of consent in any other clinical study involving an investigational study intervention or any other type of medical research.
- •Current enrolment or past participation in this clinical study.
- •Positive human immunodeficiency virus (HIV) antibody test.
- •Presence of Hepatitis B surface antigen (HbsAg) at screening or within 3 months prior to first dose of study intervention.
- •Hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
- •A positive confirmation of Coronavirus disease 2019 (COVID-19) infection, or high clinical index of suspicion for COVID-
- •The participant, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete the study.
- •Regular alcohol consumption within 6 months prior to the study. An average weekly intake of >14 units for males or females. One unit is equivalent to approximately to 8 g of alcohol: a half-pint (approximately [~]240 mL) of beer, one glass (125 mL) of wine or one (25 mL) measure of spirits.
- •Positive smoke breathalyzer indicative of smoking history at screening and each in-house admission to the clinical research unit or regular use of tobacco or nicotine-containing products (i.e., nicotine patches or vaporizing devices) within 3 months prior to screening.
- •Regular use of combustible tobacco products, and non-combustible nicotine delivery systems, inclusive of cigarettes, cigars, pipes, and materials used to "vape".
- •Any history of substance abuse or a positive urine test for drugs of abuse/ alcohol breath screen at screening or admission.
- •Known hypersensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
- •Contraindication for MDZ (i.e., Hypersensitivity to the active substance, benzodiazepines or to any of the excipients, myasthenia gravis, respiratory insufficiency, sleep apnea syndrome, severe hepatic impairment).
- •Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.).
研究组 & 干预措施
GSK3882347 and MDZ
Period 1: Participants will receive MDZ on Day 1. Period 2: Participants will receive 14-days of repeat dosing of GSK3882347 Followed by one dose of MDZ co-administered with GSK3882347 on Day 15.
干预措施: Midazolam (Drug)
GSK3882347 and MDZ
Period 1: Participants will receive MDZ on Day 1. Period 2: Participants will receive 14-days of repeat dosing of GSK3882347 Followed by one dose of MDZ co-administered with GSK3882347 on Day 15.
干预措施: GSK3882347 (Drug)
结局指标
主要结局
Period 1: Cmax of 1-hydroxy-MDZ
时间窗: Up to Day 2
Period 2: Cmax of MDZ
时间窗: Up to Day 15
Period 2: Cmax of 1-hydroxy-MDZ
时间窗: Up to Day 15
Period 1: Area under the curve from time zero to 24 hours (AUC [0-24]) for plasma concentration of MDZ
时间窗: Up to 24 hours
Period 1: AUC (0-24) for plasma concentration of 1-hydroxy-MDZ
时间窗: Up to 24 hours
Period 1: Time to Cmax (Tmax) of MDZ
时间窗: Up to Day 2
Period 2: AUC (0-24) for plasma concentration of MDZ
时间窗: Up to 24 hours
Period 2: AUC (0-24) for plasma concentration of 1-hydroxy-MDZ
时间窗: Up to 24 hours
Period 1: Tmax of 1-hydroxy-MDZ
时间窗: Up to Day 2
Period 2: Tmax of MDZ
时间窗: Up to Day 15
Period 2: Tmax of 1-hydroxy-MDZ
时间窗: Up to Day 15
Period 1: AUC from time zero to last time of quantifiable concentration (AUC [0-tau]) for plasma concentration of MDZ
时间窗: Up to Day 2
Period 1: Time lag before observation of measurable concentrations (Tlag) of MDZ
时间窗: Up to Day 2
Period 1: Tlag of 1-hydroxy-MDZ
时间窗: Up to Day 2
Period 1: AUC (0-tau) for plasma concentration of 1-hydroxy-MDZ
时间窗: Up to Day 2
Period 2: AUC (0-tau) for plasma concentration of MDZ
时间窗: Up to Day 15
Period 2: AUC (0-tau) for plasma concentration of 1-hydroxy-MDZ
时间窗: Up to Day 15
Period 1: AUC from time zero extrapolated to infinite time (AUC [0-inf]) for plasma concentration of MDZ
时间窗: Up to Day 2
Period 2: AUC (0-inf) for plasma concentration of MDZ
时间窗: Up to Day 15
Period 2: AUC (0-inf) for plasma concentration of 1-hydroxy-MDZ
时间窗: Up to Day 15
Period 2: Tlag of MDZ
时间窗: Up to Day 15
Period 2: Tlag of 1-hydroxy-MDZ
时间窗: Up to Day 15
Period 1: Time to half-life (T1/2) of MDZ
时间窗: Up to Day 2
Period 1: T1/2 of 1-hydroxy-MDZ
时间窗: Up to Day 2
Period 2: T1/2 of MDZ
时间窗: Up to Day 15
Period 1: Maximum plasma concentration (Cmax) of MDZ
时间窗: Up to Day 2
Period 2: T1/2 of 1-hydroxy-MDZ
时间窗: Up to Day 15
Period 1: AUC (0-inf) for plasma concentration of 1-hydroxy-MDZ
时间窗: Up to Day 2
次要结局
- Cmax for repeat dose of GSK3882347(Up to Day 15)
- Time invariance using AUC(0-tau) (repeat dose) of GSK3882347(Up to Day 15)
- Number of participants with clinically significant changes in vital sign values(Up to Day 15)
- AUC (0-24) for plasma concentration of GSK3882347(Up to 24 hours)
- Plasma concentrations over the dosing interval tau (Ctau) of GSK3882347(Up to Day 15)
- Oral clearance (CL/F) of GSK3882347(Up to Day 15)
- Number of participants with adverse events (AEs) and serious adverse events (SAEs)(Up to Day 15)
- Number of participants with clinically significant changes in hematology laboratory values(Up to Day 15)
- Number of participants with clinically significant changes in chemistry laboratory values(Up to Day 15)
- Number of participants with clinically significant changes in 12-lead electrocardiogram (ECG) readings(Up to Day 15)
- Volume of distribution/ Bioavailability (Vd/F) of GSK3882347(Up to Day 15)
- AUC(0-tau) for repeat dose of GSK3882347(Up to Day 15)
- Number of participants with clinically significant changes in urinalysis laboratory values(Up to Day 15)
- Mean residence time (MRT) of GSK3882347(Up to Day 15)
- AUC(0-inf) for single dose of GSK3882347(Up to Day 2)
- Cmax for single dose of GSK3882347(Up to Day 2)
- Accumulation ratio (Ro) using AUC (0-tau) for repeat dose of GSK3882347(Up to Day 15)
- Time invariance using AUC(0-inf) (single dose) of GSK3882347(Up to Day 2)
- Achievement of steady state of GSK3882347(Up to Day 15)